Open-Label, Multicenter, Dose-Escalation Expansion Phase IB study to Evaluate Safety, Pharmacokinetics, and activity of BET Inhibitor RO6870810, Given as Mono- and combination Therapy to patients with Advanced Multiple Myeloma